EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Optimising urinary catecholamine metabolite diagnostics for neuroblastoma

Yvette A H Matser iD, Iedan R N Verly iD, Maria van der Ham, Monique G M de Sain-van der Velden, Nanda M Verhoeven-Duif, Shifra Ash, Giuliana Cangemi, Sebastiano Barco, Maja Beck Popovic, André B P van Kuilenburg, Godelieve A M Tytgat iD, SIOPEN Catecholamine Working Group

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30289 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Yvette A H Matser and 11 co-authors. Institution: Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands. Major MEDLINE topics: Tandem Mass Spectrometry, Neuroblastoma. Cited 21 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma.

Methods

Twenty‐four‐hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3‐methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high‐performance liquid chromatography coupled with fluorescence detection (HPLC‐FD) and/or ultra‐performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC‐MS/MS).

Results

Catecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24‐hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24‐hour urine and spot urine samples ( p > .08 and >.27 for all metabolites). The area under the receiver‐operating‐characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p = .02). No differences were observed in metabolite levels between the two analysis methods.

Conclusion

Catecholamine metabolites in spot urine and 24‐hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.

Subjects

MeSH terms (MEDLINE)

Tandem Mass SpectrometryNeuroblastomaHumansChromatography, LiquidHomovanillic AcidMetanephrineVanilmandelic AcidMandelic Acids

Author keywords

catecholamine metabolitesdiagnostic sensitivitymetanephrinesneuroblastomatandem mass spectrometryurine collection

Substances

Homovanillic AcidMetanephrineVanilmandelic Acid3-methoxy-4-hydroxymandelic acidMandelic Acids

Authors and institutions

  • Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands.
  • Laboratory of Genetic Metabolic Diseases, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Ruth Rappaport Children's Hospital, Haifa, Israel.
  • Central Laboratory of Analyses Chromatography and Mass Spectrometry Section, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • University Hospital Lausanne, Lausanne, Switzerland.

ORCID profiles: Yvette A H Matser, Iedan R N Verly, Godelieve A M Tytgat

Cite

APA

Matser, Y. A. H., Verly, I. R. N., van der Ham, M., de Sain-van der Velden, M. G. M., Verhoeven-Duif, N. M., Ash, S., Cangemi, G., Barco, S., Popovic, M. B., van Kuilenburg, A. B. P., Tytgat, G. A. M., & SIOPEN Catecholamine Working Group (2023). Optimising urinary catecholamine metabolite diagnostics for neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30289

Vancouver

Matser YAH, Verly IRN, van der Ham M, de Sain-van der Velden MGM, Verhoeven-Duif NM, Ash S, et al. Optimising urinary catecholamine metabolite diagnostics for neuroblastoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30289

BibTeX
@article{Matser2023,
  author = {Matser, Yvette A H and Verly, Iedan R N and van der Ham, Maria and de Sain-van der Velden, Monique G M and Verhoeven-Duif, Nanda M and Ash, Shifra and Cangemi, Giuliana and Barco, Sebastiano and Popovic, Maja Beck and van Kuilenburg, André B P and Tytgat, Godelieve A M and SIOPEN Catecholamine Working Group, SIOPEN Catecholamine Working Group},
  title = {Optimising urinary catecholamine metabolite diagnostics for neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30289}
}
Start for free →